Skip to main navigation
Skip to search
Skip to main content
WashU Medicine Research Profiles Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
Tumor necrosis factor inhibitor-associated dermatomyositis
Rachel Klein
, Misha Rosenbach
, Ellen J. Kim
, Brian Kim
, Victoria P. Werth
, Jonathan Dunham
Division of Dermatology
Roy and Diana Vagelos Division of Biology & Biomedical Sciences (DBBS)
Institute of Clinical and Translational Sciences (ICTS)
Siteman Cancer Center
COVID-19 Researchers
Bursky Center for Human Immunology & Immunotherapy Programs (CHiiPs)
Research output
:
Contribution to journal
›
Article
›
peer-review
119
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Tumor necrosis factor inhibitor-associated dermatomyositis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Pharmacology, Toxicology and Pharmaceutical Science
Tumor Necrosis Factor Inhibitor
100%
Dermatomyositis
100%
Autoimmune Disease
28%
Rheumatoid Arthritis
14%
Etanercept
14%
Adalimumab
14%
Inflammation
14%
Immunosuppressive Agent
14%
Syndrome
14%
Rash
14%
Vasculitis
14%
Muscle Weakness
14%
Inflammatory Arthritis
14%
Diseases
14%
Keyphrases
Tumour Necrosis Factor Inhibitor (TNFi)
100%
Dermatomyositis
100%
Autoimmune Disease
28%
Etanercept
14%
Adalimumab
14%
Inflammation
14%
Corticosteroids
14%
Rash
14%
Vasculitis
14%
Inflammatory Arthritis
14%
Muscle Weakness
14%
Unknown Etiology
14%
Immunosuppressive Medication
14%
Medicine and Dentistry
Dermatomyositis
100%
TNF Inhibitor
100%
Autoimmune Disease
28%
Immunosuppressive Drug
14%
Rheumatoid Arthritis
14%
Exanthem
14%
Vasculitis
14%
Muscle Weakness
14%
Etanercept
14%
Adalimumab
14%
Inflammatory Arthritis
14%
Diseases
14%
Immunology and Microbiology
Dermatomyositis
100%
TNF Inhibitor
100%
Autoimmune Disease
28%
Muscle
28%
Immunosuppressive Drug
14%
Inflammatory Arthritis
14%
Vasculitis
14%
Etanercept
14%
Adalimumab
14%